NewCardio Announces Acceptance of Five Peer-Reviewed Publications

NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology provider, announced today that five of its most recent medical and technical submissions have been accepted for publication in prominent peer-reviewed medical journals. These publications will present important clinical data supporting the accuracy and effectiveness of its CardioBip™ and Cardio3KG™ products.

• The peer-reviewed cardiology journal Heart Rhythm, published by the Heart Rhythm Society, has accepted a manuscript entitled "Vectorcardiographic diagnosis of new and old left bundle branch block,” by Alexei Shvilkin, M.D., Ph.D., Kalon Ho, M.D., Peter Zimetbaum, M.D., and Mark Josephson M.D. of Beth Israel Deaconess Medical Center and Harvard Medical School, and Bosko Bojovic, Ph.D., Branislav Vajdic, Ph.D. and Ihor Gussak, M.D., Ph.D., of NewCardio. This study presents data showing the ability of the Cardio3KG to improve diagnosis of acute myocardial infarction in a subgroup of patients with significant ECG abnormalities prior to the acute event. Publication and release of the manuscript is anticipated this year.
• Two full-length manuscripts incorporating data from clinical studies of CardioBip have been selected by peer-reviewers for publication this year in the IEEE Engineering in Medicine and Biology Journal. The clinical studies were conducted in two distinct groups of cardiac disease patients: those with established coronary artery disease who are at increased risk of myocardial infarction, i.e. a heart attack; and patients with recurrent atrial fibrillation, who are at increased risk of stroke. In both groups, the data show that CardioBip accurately detected and wirelessly transmitted important electrocardiographic changes indicating increased risk of adverse cardiac events in these patients.
• In addition, the Journal of Electrocardiology plans to publish two editorials coauthored by Dr. Ihor Gussak, M.D., PhD, NewCardio’s Chief Medical Officer, with Drs. P. Bjerregaard, H. Nallapaneni, and R. Shah, in the September 2010 issue of the Journal. The editorials cover important aspects relating to clinical and drug-development aspects of the Short QT Interval and its pro-arrhythmic potential. The editorials are relevant to the Company’s QTinno™ product, and accurate detection and quantification of drug-induced risk of cardiac arrhythmias.

Branislav Vajdic, Ph.D., NewCardio’s CEO, commented, "We are delighted that the peer-reviewers from these prestigious journals selected these important manuscripts for publication, and are especially grateful to our outstanding academic medical collaborators who designed and carried out this work. These publications will add to the strong clinical evidence for the use of CardioBip and Cardio3KG in diagnosing and monitoring patients with coronary disease and atrial fibrillation, two very common and serious cardiac diseases. Moreover, we believe this acceptance for publication is further evidence that our products and solutions are gaining increasing recognition by the scientific and medical communities. In particular we are pleased that CardioBip is being seen as a real solution in the growing telemedicine arena.”

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead ECG. NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0